Abstract 392P
Background
ROS1 fusions (ROS1+) are enriched in 1-2% of non-small cell lung cancer (NSCLC) cases. SAF-189s is a novel, next-generation ALK/ROS1 inhibitor which overcomes multiple resistance mutations. We explored the efficacy and safety of SAF-189s in phase (Ph) 2 study in patients (pts) with ROS1 fusion NSCLC, with or without ROS1 inhibitor treatment.
Methods
This multicenter, single-arm, open-label, Ph2 study enrolled Chinese patients with advanced ROS1+ NSCLC. The study included 2 cohorts: ROS1 inhibitor (ROS1i)-naïve or crizotinib-pretreated pts in a Ph2a cohort receiving SAF-189s with dose escalation (80, 120, 160 and 210 mg doses QD), and ROS1i-naïve pts alone in a Ph2b cohort receiving 160 mg QD. The primary endpoint was Independent Review Committee (IRC)-assessed overall response rate (ORR).
Results
Between Dec 12, 2021 and Mar 25, 2022, 48 and 56 pts were enrolled in the Ph2a and 2b cohorts, respectively. IRC-confirmed ORR in ROS1i-naïve pts were 94.1% and 80.4% and DCR were 94.1% and 96.4% in pts in Ph2a and Ph2b respectively. Notably, confirmed ORRs and DCRs were similar in pts with and without brain metastasis (Table). Median PFS was 16.5 mo in Ph 2a and not reached in Ph 2b. In crizotinib-pretreated pts in Ph2a, confirmed ORR was 40% and median PFS was 5.5 mo. The majority of treatment-related adverse events (TRAEs) were grade 1 or 2. Grade ≥3 TRAEs were observed in 29.2% and 21.4% of pts in the two cohorts, respectively. Only one pt experienced a grade 4 TRAE in 210 mg dosage of Ph2a. Treatment related SAEs were reported in 10.4% and 8.9% of pts, respectively. No treatment-related deaths were reported.
Conclusions
These findings demonstrate the promising clinical activity and a tolerable toxicity profile of SAF-189s in pts with advanced ROS1+ NSCLC, with or without crizotinib treatment. Clinical trial identification NCT04237805.
Clinical trial identification
NCT04237805.
Editorial acknowledgement
Editorial assistance was provided by Jacqi Pan of Parexel, and funded by Fosun Pharma.
Legal entity responsible for the study
Wanbang Biopharmaceuticals.
Funding
Wanbang Biopharmaceuticals.
Disclosure
Y. Wu: Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Research Grant: BMS, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
384P - Prevalence of fibroblast growth factor receptor 2b (FGFR2b) protein overexpression in squamous non-small cell lung cancer (sqNSCLC)
Presenter: Hiroaki Akamatsu
Session: Poster viewing 05.
385P - Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
Presenter: Si-Yang Liu
Session: Poster viewing 05.
386P - Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutation
Presenter: Xin Li
Session: Poster viewing 05.
387P - Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Presenter: Hidehito Horinouchi
Session: Poster viewing 05.
388P - Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
Presenter: Yi-Long Wu
Session: Poster viewing 05.
389P - Updated efficacy and safety of pralsetinib in Chinese patients with advanced RET fusion+ non-small cell lung cancer
Presenter: Zhou Qing
Session: Poster viewing 05.
390P - Entrectinib in Japanese patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
Presenter: Haruyasu Murakami
Session: Poster viewing 05.
391P - Demographics, treatment patterns and clinical outcomes in ROS1-positive non-small cell lung cancer: A referral tertiary cancer centre experience from a low-middle income country
Presenter: Goutam Panda
Session: Poster viewing 05.
394P - Research of the algorithm for rare driver genes in non-small cell lung cancer using pathological images and artificial intelligence
Presenter: Kiyotaka Yoh
Session: Poster viewing 05.
395P - Molecular landscape of Indian NSCLC: Is NGS the answer?
Presenter: Ullas Batra
Session: Poster viewing 05.